(RTTNews) - While reporting financial results for the first quarter on Thursday, medical technology company AngioDynamics, Inc. (ANGO) reiterated its adjusted loss and net sales guidance for the full year 2027, based on its first quarter performance and current outlook for the re
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.